CorWave

The 46th ISHLT Annual Meeting was a great opportunity for CorWave to connect and partner with the scientific community as we move forward with our ongoing clinical study and prepare for the pivotal phase. At the Late Breaking Science in Heart Transplantation and MCS, A/Prof Kavitha Muthiah from St Vincent's Health Australia presented the latest insights from CorWave’s First-In-Human (FIH) study: ➡️500 cumulative days of support ➡️Full hemodynamic support and preserved pulsatile flow ➡️All patients successfully bridged to transplant A heartfelt thank you to the St Vincent's Health Australia team for their outstanding partnership, and to all leading experts for the enriching discussions. We look forward to shaping the future of MCS together! #CorWave #ISHLT2026 #HeartFailure #Innovation #MCS #Cardiology ISHLT - International Society for Heart and Lung Transplantation [𝘛𝘩𝘦 𝘊𝘰𝘳𝘞𝘢𝘷𝘦 𝘓𝘝𝘈𝘚 𝘪𝘴 𝘢𝘯 𝘪𝘯𝘷𝘦𝘴𝘵𝘪𝘨𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘥𝘦𝘷𝘪𝘤𝘦 𝘤𝘶𝘳𝘳𝘦𝘯𝘵𝘭𝘺 𝘶𝘯𝘥𝘦𝘳𝘨𝘰𝘪𝘯𝘨 𝘤𝘭𝘪𝘯𝘪𝘤𝘢𝘭 𝘦𝘷𝘢𝘭𝘶𝘢𝘵𝘪𝘰𝘯. 𝘐𝘵 𝘪𝘴 𝘯𝘰𝘵 𝘺𝘦𝘵 𝘢𝘱𝘱𝘳𝘰𝘷𝘦𝘥 𝘧𝘰𝘳 𝘤𝘰𝘮𝘮𝘦𝘳𝘤𝘪𝘢𝘭 𝘶𝘴𝑒 𝑖𝑛 𝑎𝑛𝑦 𝑐𝑜𝑢𝑛𝑡𝑟𝑦.]

CorWave strengthens its leadership team with two key appointments 👇   We are delighted to welcome Andreas Fleischli as Chief Technology Officer and Daniel Lexcen, MS, PhD as Vice President Clinical & Scientific Affairs. 🔷 Andreas Fleischli brings about 30 years of expertise in the development of LVADs. As an internationally recognized authority in magnetically levitated pump technologies, he played a key role in pioneering and manufacturing at scale the most implanted LVAD worldwide to date, a product that has generated over $4 billion in cumulative revenues. He replaces Carl Botterbusch, who is retiring. We warmly thank Carl for his years of dedication and contribution to CorWave 🙏 🔷 Daniel Lexcen, MS, PhD joins CorWave with extensive experience in heart failure clinical research and global clinical program execution. Over the past decade, he contributed to the design and execution of numerous international clinical trials across the United States, Europe, Australia, and Japan. His experience spans the full product development lifecycle, from early clinical studies to post-market programs. Prior to joining CorWave, Daniel led the global clinical research strategy for cardiac rhythm at Medtronic.   Alongside the recent arrival of Dawn Sadlowski-Buisserez as VP of Operations, these appointments complete a leadership team capable of transitioning CorWave from a breakthrough R&D firm to a global industry leader. Read more about their journey 👉 https://lnkd.in/eWHaQVQF #CorWavers #Leadership #MedTech #Innovation #HeartFailure #LVAD

Over the past few weeks, we have been pleased to share updates with the mechanical circulatory support community across several conferences on our ongoing First-in-Human study, highlighting more than a year of cumulative clinical experience. As highlighted by our clinical team, Daniel Lexcen, MS, PhD at #THT2026 and Rémi Pruvost at the European Mechanical Circulatory Support Summit - EUMS, the device achieved the following outcomes in the first patients: ✅ 30-day survival endpoint ✅ Full hemodynamic support ✅ Physiologic flow contrasting with contemporary continuous-flow devices We warmly thank the teams at St Vincent's Health Australia for their outstanding collaboration as we near completion of this study, and the EUMS and THT teams for hosting such valuable summits for our community. [𝘛𝘩𝘦 𝘊𝘰𝘳𝘞𝘢𝘷𝘦 𝘓𝘝𝘈𝘚 𝘪𝘴 𝘢𝘯 𝘪𝘯𝘷𝘦𝘴𝘵𝘪𝘨𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘥𝘦𝘷𝘪𝘤𝘦 𝘤𝘶𝘳𝘳𝘦𝘯𝘵𝘭𝘺 𝘶𝘯𝘥𝘦𝘳𝘨𝘰𝘪𝘯𝘨 𝘤𝘭𝘪𝘯𝘪𝘤𝘢𝘭 𝘦𝘷𝘢𝘭𝘶𝘢𝘵𝘪𝘰𝘯. 𝘐𝘵 𝘪𝘴 𝘯𝘰𝘵 𝘺𝘦𝘵 𝘢𝘱𝘱𝘳𝘰𝘷𝘦𝘥 𝘧𝘰𝘳 𝘤𝘰𝘮𝘮𝘦𝘳𝘤𝘪𝘢𝘭 𝘶𝘴𝑒 𝑖𝑛 𝑎𝑛𝑦 𝑐𝑜𝑢𝑛𝑡𝑟𝑦.]   #EUMS2026 #THT2026 #LVAS #HeartFailure #MedTech #Innovation

A few months ago, two pallets carrying CorWave systems left our facilities for Australia 📦 This moment brought all CorWavers together. It symbolizes what hundreds of people have been building with persistence and conviction since CorWave’s inception: the clinical realization of our wave membrane heart pump 🫀   Shortly thereafter, the outstanding clinical team at St Vincent's Private Hospital Sydney successfully implanted our life-saving devices in two Australian patients. 2025 marks the beginning of our clinical journey. From 2026 onward, in close partnership with the clinical community, we will work to turn this first milestone into a historic step, delivering meaningful improvements in patients’ lives through our wave membrane technology. As this new year begins, we would like to extend our sincere thanks and best wishes to everyone who supports and follows us, from our investors to the mechanical circulatory support community. We look forward to continuing our clinical studies and contributing to the growing need for innovation to improve the lives of patients with advanced heart failure. Wishing you all a very Happy New Year. [𝘛𝘩𝘦 𝘊𝘰𝘳𝘞𝘢𝘷𝘦 𝘓𝘝𝘈𝘚 𝘪𝘴 𝘢𝘯 𝘪𝘯𝘷𝘦𝘴𝘵𝘪𝘨𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘥𝘦𝘷𝘪𝘤𝘦 𝘤𝘶𝘳𝘳𝘦𝘯𝘵𝘭𝘺 𝘶𝘯𝘥𝘦𝘳𝘨𝘰𝘪𝘯𝘨 𝘤𝘭𝘪𝘯𝘪𝘤𝘢𝘭 𝘦𝘷𝘢𝘭𝘶𝘢𝘵𝘪𝘰𝘯. 𝘐𝘵 𝘪𝘴 𝘯𝘰𝘵 𝘺𝘦𝘵 𝘢𝘱𝘱𝘳𝘰𝘷𝘦𝘥 𝘧𝘰𝘳 𝘤𝘰𝘮𝘮𝘦𝘳𝘤𝘪𝘢𝘭 𝘶𝘴𝘦.] #innovation #LVAS #medtech #heartfailure #heartpump

At the 31st Annual Meeting of the ISMCS - International Society for Mechanical Circulatory Support , Prof. Christopher Hayward from St Vincent's Health Australia presented the latest insights from the first two successful implants of the CorWave LVAS, highlighting:   ✅ 30-day survival without adverse events ✅ Full hemodynamic support ✅ Physiologic, pulsatile flow distinct from today’s continuous-flow devices ✅ Patient 1: successfully bridged to heart transplantation ✅ Patient 2: transpulmonary gradient reversed and relisted for transplantation, discharged home, and now approaching six months of support with the CorWave LVAS   We are deeply grateful to the St Vincent’s team for their collaboration, including Desirée Robson’s poster presentation at #ISMCS2025. Thank you as well to Rémi Pruvost, for his session focused on the technology and engineering behind the CorWave LVAS.   Our sincere appreciation goes to ISMCS President Daniel Zimpfer and his team for another outstanding edition of the conference, and to all the clinicians and researchers we had the pleasure to meet and exchange with. 🙏   [𝘛𝘩𝘦 𝘊𝘰𝘳𝘞𝘢𝘷𝘦 𝘓𝘝𝘈𝘚 𝘪𝘴 𝘢𝘯 𝘪𝘯𝘷𝘦𝘴𝘵𝘪𝘨𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘥𝘦𝘷𝘪𝘤𝘦 𝘤𝘶𝘳𝘳𝘦𝘯𝘵𝘭𝘺 𝘶𝘯𝘥𝘦𝘳𝘨𝘰𝘪𝘯𝘨 𝘤𝘭𝘪𝘯𝘪𝘤𝘢𝘭 𝘦𝘷𝘢𝘭𝘶𝘢𝘵𝘪𝘰𝘯. 𝘐𝘵 𝘪𝘴 𝘯𝘰𝘵 𝘺𝘦𝘵 𝘢𝘱𝘱𝘳𝘰𝘷𝘦𝘥 𝘧𝘰𝘳 𝘤𝘰𝘮𝘮𝘦𝘳𝘤𝘪𝘢𝘭 𝘶𝘴𝘦.]   #ISMCS2025 #LVAD #HeartFailure #MedTech #Innovation

CorWave is strengthening its ongoing dialogue with the cardiothoracic community at the 9th EACTS - European Association for Cardio-Thoracic Surgery Mechanical Circulatory Support Summit in Berlin.   This year’s meeting offered a valuable platform to engage with leading experts in mechanical circulatory support. During the summit, cardiac surgeon Sebastian Schulte Eistrup presented the latest clinical insights from the first two patients implanted with CorWave’s LVAS:   ➡️ Both patients have successfully reached the primary endpoint, and the device has now accumulated over 8 months of patient support. ➡️ Initial clinical experience continues to highlight CorWave LVAS’s unique ability to preserve physiological pulsatility in various clinical settings, demonstrating the potential of our next-generation membrane-based technology for patients with advanced heart failure.   This presentation comes as CorWave continues to progress toward the next stages of clinical development, including the preparation of its pivotal trials.   We extend our sincere appreciation to the organizers, Gloria Färber, Jan Gummert, Daniel Zimpfer, Ivan Netuka, and Volker Falk, as well as to all attendees for fostering such high-level scientific and medical discussions. [𝘊𝘰𝘳𝘞𝘢𝘷𝘦 𝘓𝘝𝘈𝘚 𝘪𝘴 𝘢𝘯 𝘪𝘯𝘷𝘦𝘴𝘵𝘪𝘨𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘥𝘦𝘷𝘪𝘤𝘦, 𝘤𝘶𝘳𝘳𝘦𝘯𝘵𝘭𝘺 𝘶𝘯𝘥𝘦𝘳𝘨𝘰𝘪𝘯𝘨 𝘤𝘭𝘪𝘯𝘪𝘤𝘢𝘭 𝘦𝘷𝘢𝘭𝘶𝘢𝘵𝘪𝘰𝘯. 𝘐𝘵 𝘪𝘴 𝘯𝘰𝘵 𝘺𝘦𝘵 𝘢𝘱𝘱𝘳𝘰𝘷𝘦𝘥 𝘧𝘰𝘳 𝘤𝘰𝘮𝘮𝘦𝘳𝘤𝘪𝘢𝘭 𝘶𝘴𝘦.]   #EACTSMCS2025 #LVAD #heartfailure #medtech #innovation

CorWave LVAS is a “quantum leap” in heart pump technology.   We would like to thank Dr. Paul Jansz, who yesterday delivered the first-ever surgical presentation of the CorWave LVAS at the Techno-College during the 39th Annual Meeting of the EACTS - European Association for Cardio-Thoracic Surgery in Copenhagen.   Before an international audience of several hundred cardiothoracic surgeons, Dr. Jansz shared insights from the First-in-Human implantation of our heart pump, which he led at St Vincent's Health Australia, highlighting key clinical outcomes:   🔹 A standardized and streamlined surgical approach grounded in experience from thousands of LVAD implantations 🔹 No device-related serious adverse events 🔹 Pulsatility preserved throughout the study, with beat-to-beat valve opening 🔹 Successful transplantation after 84 days of support and no thrombus observed at explant   🎙️ “𝘐 𝘵𝘩𝘪𝘯𝘬 𝘵𝘩𝘪𝘴 𝘪𝘴 𝘢 𝘲𝘶𝘢𝘯𝘵𝘶𝘮 𝘭𝘦𝘢𝘱 𝘪𝘯 𝘵𝘦𝘳𝘮𝘴 𝘰𝘧 𝘥𝘦𝘷𝘪𝘤𝘦𝘴. 𝘞𝘦'𝘷𝘦 𝘨𝘰𝘵 𝘧𝘶𝘭𝘭 𝘴𝘶𝘱𝘱𝘰𝘳𝘵 𝘢𝘯𝘥 𝘱𝘶𝘭𝘴𝘢𝘵𝘪𝘭𝘦 𝘴𝘶𝘱𝘱𝘰𝘳𝘵 𝘵𝘩𝘢𝘵 𝘐 𝘩𝘢𝘷𝘦𝘯'𝘵 𝘴𝘦𝘦𝘯 𝘣𝘦𝘧𝘰𝘳𝘦”, he concluded. [𝘊𝘰𝘳𝘞𝘢𝘷𝘦 𝘓𝘝𝘈𝘚 𝘪𝘴 𝘢𝘯 𝘪𝘯𝘷𝘦𝘴𝘵𝘪𝘨𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘥𝘦𝘷𝘪𝘤𝘦, 𝘤𝘶𝘳𝘳𝘦𝘯𝘵𝘭𝘺 𝘶𝘯𝘥𝘦𝘳𝘨𝘰𝘪𝘯𝘨 𝘤𝘭𝘪𝘯𝘪𝘤𝘢𝘭 𝘦𝘷𝘢𝘭𝘶𝘢𝘵𝘪𝘰𝘯. 𝘐𝘵 𝘪𝘴 𝘯𝘰𝘵 𝘺𝘦𝘵 𝘢𝘱𝘱𝘳𝘰𝘷𝘦𝘥 𝘧𝘰𝘳 𝘤𝘰𝘮𝘮𝘦𝘳𝘤𝘪𝘢𝘭 𝘶𝘴𝘦.] #EACTS2025 #innovation #medtech #LVAS #CardiothoracicSurgery #heartfailure

𝗘𝗔𝗖𝗧𝗦 𝗶𝘀 𝗰𝗮𝗹𝗹𝗶𝗻𝗴! 🫀📡 Next week, Dr. Paul Jansz, cardiothoracic surgeon at St Vincent's Health Australia, will deliver the first surgical presentation on CorWave LVAS at the Techno-College during the 39th EACTS - European Association for Cardio-Thoracic Surgery Annual Meeting in Copenhagen organized under the leadership of EACTS President Prof. Volkmar Falk. Last May, Dr. Jansz and his team performed the world’s first-in-human implant of a heart pump based on wave-membrane technology. He will now share his experience and insights from this procedure with exclusive surgical footage 😷 🎥. Be sure to attend Techno-College, the showcase for breakthrough innovations in cardiothoracic surgery, to learn more about CorWave's FIH.  🔔Save the date 📅 Wednesday October 8 ⏱️ 3:05 PM (CEST) 📍 Hall A1, Copenhagen   [𝘊𝘰𝘳𝘞𝘢𝘷𝘦 𝘓𝘝𝘈𝘚 𝘪𝘴 𝘢𝘯 𝘪𝘯𝘷𝘦𝘴𝘵𝘪𝘨𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘥𝘦𝘷𝘪𝘤𝘦, 𝘤𝘶𝘳𝘳𝘦𝘯𝘵𝘭𝘺 𝘶𝘯𝘥𝘦𝘳𝘨𝘰𝘪𝘯𝘨 𝘤𝘭𝘪𝘯𝘪𝘤𝘢𝘭 𝘦𝘷𝘢𝘭𝘶𝘢𝘵𝘪𝘰𝘯. 𝘐𝘵 𝘪𝘴 𝘯𝘰𝘵 𝘺𝘦𝘵 𝘢𝘱𝘱𝘳𝘰𝘷𝘦𝘥 𝘧𝘰𝘳 𝘤𝘰𝘮𝘮𝘦𝘳𝘤𝘪𝘢𝘭 𝘶𝘴𝘦.] #EACTS2025 #innovation #medtech #LVAS #CardiothoracicSurgery #heartfailure

𝗣𝘂𝗹𝘀𝗮𝘁𝗶𝗹𝗶𝘁𝘆 𝗶𝘀 𝗯𝗮𝗰𝗸! 💓   We are thrilled to share the Late Breaking Results of CorWave’s First-in-Human Implant, following the presentation by Prof. Christopher Hayward at the Heart Failure Society of America Annual Meeting 👇   🎙️ "𝘛𝘩𝘦 𝘱𝘩𝘺𝘴𝘪𝘰𝘭𝘰𝘨𝘪𝘤 𝘱𝘶𝘭𝘴𝘦 𝘵𝘩𝘢𝘵 𝘸𝘦 𝘰𝘣𝘴𝘦𝘳𝘷𝘦𝘥 𝘪𝘯 𝘵𝘩𝘦 𝘧𝘪𝘳𝘴𝘵 𝘊𝘰𝘳𝘞𝘢𝘷𝘦 𝘱𝘢𝘵𝘪𝘦𝘯𝘵 𝘴𝘵𝘢𝘯𝘥𝘴 𝘰𝘶𝘵. 𝘛𝘩𝘪𝘴 𝘧𝘪𝘳𝘴𝘵 𝘦𝘹𝘱𝘦𝘳𝘪𝘦𝘯𝘤𝘦 𝘴𝘶𝘨𝘨𝘦𝘴𝘵𝘴 𝘵𝘩𝘢𝘵 𝘵𝘩𝘦 𝘊𝘰𝘳𝘞𝘢𝘷𝘦 𝘓𝘝𝘈𝘚 𝘤𝘢𝘯 𝘣𝘦 𝘪𝘮𝘱𝘭𝘢𝘯𝘵𝘦𝘥 𝘴𝘢𝘧𝘦𝘭𝘺 𝘢𝘯𝘥 𝘩𝘢𝘴 𝘵𝘩𝘦 𝘱𝘰𝘵𝘦𝘯𝘵𝘪𝘢𝘭 𝘵𝘰 𝘰𝘧𝘧𝘦𝘳 𝘴𝘪𝘨𝘯𝘪𝘧𝘪𝘤𝘢𝘯𝘵 𝘣𝘦𝘯𝘦𝘧𝘪𝘵𝘴 𝘧𝘰𝘳 𝘱𝘢𝘵𝘪𝘦𝘯𝘵𝘴 𝘸𝘪𝘵𝘩 𝘩𝘦𝘢𝘳𝘵 𝘧𝘢𝘪𝘭𝘶𝘳𝘦,” commented Prof. Christopher Hayward, Principal Investigator of the study.    We are deeply grateful to St Vincent's Health Australia’s clinical team and to the CorWave engineering team behind this world first. 🙏 [𝘊𝘰𝘳𝘞𝘢𝘷𝘦 𝘓𝘝𝘈𝘚 𝘪𝘴 𝘢𝘯 𝘪𝘯𝘷𝘦𝘴𝘵𝘪𝘨𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘥𝘦𝘷𝘪𝘤𝘦, 𝘤𝘶𝘳𝘳𝘦𝘯𝘵𝘭𝘺 𝘶𝘯𝘥𝘦𝘳𝘨𝘰𝘪𝘯𝘨 𝘤𝘭𝘪𝘯𝘪𝘤𝘢𝘭 𝘦𝘷𝘢𝘭𝘶𝘢𝘵𝘪𝘰𝘯. 𝘐𝘵 𝘪𝘴 𝘯𝘰𝘵 𝘺𝘦𝘵 𝘢𝘱𝘱𝘳𝘰𝘷𝘦𝘥 𝘧𝘰𝘳 𝘤𝘰𝘮𝘮𝘦𝘳𝘤𝘪𝘢𝘭 𝘶𝘴𝘦.]   #HFSA2025 #FirstInHuman #ClinicalTrial #LVAS #Innovation #Medtech #HeartFailure #WorldHeartDay

D-4 ⌛ On Sunday morning, Prof. Christopher Hayward will present the Late-Breaking Results of CorWave's First-in-Human Implant at the 2025 Heart Failure Society of America Annual Meeting. Join the "Transplant and VADs" late-breaking clinical research session in "MCC - Ballroom A" starting at 10:45am to learn more about this  world's first and witness the comeback of pulsatility 💓. [𝘊𝘰𝘳𝘞𝘢𝘷𝘦 𝘓𝘝𝘈𝘚 𝘪𝘴 𝘢𝘯 𝘪𝘯𝘷𝘦𝘴𝘵𝘪𝘨𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘥𝘦𝘷𝘪𝘤𝘦, 𝘤𝘶𝘳𝘳𝘦𝘯𝘵𝘭𝘺 𝘶𝘯𝘥𝘦𝘳𝘨𝘰𝘪𝘯𝘨 𝘤𝘭𝘪𝘯𝘪𝘤𝘢𝘭 𝘦𝘷𝘢𝘭𝘶𝘢𝘵𝘪𝘰𝘯. 𝘐𝘵 𝘪𝘴 𝘯𝘰𝘵 𝘺𝘦𝘵 𝘢𝘱𝘱𝘳𝘰𝘷𝘦𝘥 𝘧𝘰𝘳 𝘤𝘰𝘮𝘮𝘦𝘳𝘤𝘪𝘢𝘭 𝘶𝘴𝘦.] #FirstInHuman #ClinicalTrial #LVAS #Innovation #Medtech #HeartFailure